Merck & Company Inc (MRK)vsTherapeuticsMD Inc (TXMD)
MRK
Merck & Company Inc
$120.79
-1.42%
HEALTHCARE · Cap: $285.64B
TXMD
TherapeuticsMD Inc
$2.00
+1.52%
HEALTHCARE · Cap: $21.07M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1961367% more annual revenue ($65.77B vs $3.35M). MRK leads profitability with a 13.6% profit margin vs 5.3%. MRK trades at a lower P/E of 32.6x. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
TXMD
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Intrinsic value data unavailable for TXMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Reasonable price relative to book value
Revenue surging 84.2% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.7% — below average capital efficiency
5.3% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : TXMD
The strongest argument for TXMD centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 84.2% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : TXMD
The primary concerns for TXMD are EPS Growth, Market Cap, Return on Equity. A P/E of 182.0x leaves little room for execution misses.
Key Dynamics to Monitor
MRK profiles as a value stock while TXMD is a hypergrowth play — different risk/reward profiles.
TXMD carries more volatility with a beta of 0.58 — expect wider price swings.
TXMD is growing revenue faster at 84.2% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 41/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →TherapeuticsMD Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
TherapeuticsMD, Inc. is a women's healthcare company in the United States. The company is headquartered in Boca Raton, Florida.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?